WO2014133327A1 - 인슐린 위치 특이적 결합체 - Google Patents
인슐린 위치 특이적 결합체 Download PDFInfo
- Publication number
- WO2014133327A1 WO2014133327A1 PCT/KR2014/001597 KR2014001597W WO2014133327A1 WO 2014133327 A1 WO2014133327 A1 WO 2014133327A1 KR 2014001597 W KR2014001597 W KR 2014001597W WO 2014133327 A1 WO2014133327 A1 WO 2014133327A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- insulin
- region
- immunoglobulin
- amino acid
- peptidyl polymer
- Prior art date
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title claims abstract description 421
- 108090001061 Insulin Proteins 0.000 title claims abstract description 214
- 102000004877 Insulin Human genes 0.000 title claims abstract description 213
- 229940125396 insulin Drugs 0.000 title claims abstract description 212
- 229920000642 polymer Polymers 0.000 claims abstract description 97
- 108060003951 Immunoglobulin Proteins 0.000 claims abstract description 79
- 102000018358 immunoglobulin Human genes 0.000 claims abstract description 79
- 238000000034 method Methods 0.000 claims abstract description 56
- 125000000539 amino acid group Chemical group 0.000 claims abstract description 52
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 25
- 238000001727 in vivo Methods 0.000 claims abstract description 13
- 238000002360 preparation method Methods 0.000 claims abstract description 9
- 230000001965 increasing effect Effects 0.000 claims abstract description 8
- 125000001151 peptidyl group Chemical group 0.000 claims description 81
- 125000003277 amino group Chemical group 0.000 claims description 26
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 22
- 229920001223 polyethylene glycol Polymers 0.000 claims description 18
- 239000002202 Polyethylene glycol Substances 0.000 claims description 16
- 150000001413 amino acids Chemical class 0.000 claims description 16
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical class O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 10
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N Butyraldehyde Chemical group CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 claims description 9
- 238000009472 formulation Methods 0.000 claims description 8
- 239000012634 fragment Substances 0.000 claims description 8
- 206010012601 diabetes mellitus Diseases 0.000 claims description 7
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 7
- DRLIANXPAARUMI-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) pentanoate Chemical compound CCCCC(=O)ON1C(=O)CCC1=O DRLIANXPAARUMI-UHFFFAOYSA-N 0.000 claims description 6
- 239000000556 agonist Substances 0.000 claims description 6
- 150000001299 aldehydes Chemical class 0.000 claims description 6
- 150000002466 imines Chemical class 0.000 claims description 6
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 claims description 6
- 230000004048 modification Effects 0.000 claims description 6
- 238000012986 modification Methods 0.000 claims description 6
- 230000002459 sustained effect Effects 0.000 claims description 6
- 239000000539 dimer Substances 0.000 claims description 5
- -1 succinimidyl carboxymethyl Chemical group 0.000 claims description 5
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 4
- 229920002101 Chitin Polymers 0.000 claims description 4
- 229920002307 Dextran Polymers 0.000 claims description 4
- NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical group CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 claims description 4
- 125000003172 aldehyde group Chemical group 0.000 claims description 4
- 229940053198 antiepileptics succinimide derivative Drugs 0.000 claims description 4
- 229920002988 biodegradable polymer Polymers 0.000 claims description 4
- 239000004621 biodegradable polymer Substances 0.000 claims description 4
- 229920001577 copolymer Polymers 0.000 claims description 4
- 150000004676 glycans Chemical class 0.000 claims description 4
- 229920002674 hyaluronan Polymers 0.000 claims description 4
- 229960003160 hyaluronic acid Drugs 0.000 claims description 4
- 229940072221 immunoglobulins Drugs 0.000 claims description 4
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims description 4
- 150000002632 lipids Chemical class 0.000 claims description 4
- 229920001583 poly(oxyethylated polyols) Polymers 0.000 claims description 4
- 229920001451 polypropylene glycol Polymers 0.000 claims description 4
- 229920001282 polysaccharide Polymers 0.000 claims description 4
- 239000005017 polysaccharide Substances 0.000 claims description 4
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 4
- 238000006467 substitution reaction Methods 0.000 claims description 4
- DKXIKPOYTWCGIE-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 2-methylbutanoate Chemical compound CCC(C)C(=O)ON1C(=O)CCC1=O DKXIKPOYTWCGIE-UHFFFAOYSA-N 0.000 claims description 3
- FHNMAOLQZHUPIJ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 2-methylpropanoate Chemical compound CC(C)C(=O)ON1C(=O)CCC1=O FHNMAOLQZHUPIJ-UHFFFAOYSA-N 0.000 claims description 3
- DYMYLBQTHCJHOQ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) butanoate Chemical compound CCCC(=O)ON1C(=O)CCC1=O DYMYLBQTHCJHOQ-UHFFFAOYSA-N 0.000 claims description 3
- ZJIFDEVVTPEXDL-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) hydrogen carbonate Chemical compound OC(=O)ON1C(=O)CCC1=O ZJIFDEVVTPEXDL-UHFFFAOYSA-N 0.000 claims description 3
- AASBXERNXVFUEJ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) propanoate Chemical compound CCC(=O)ON1C(=O)CCC1=O AASBXERNXVFUEJ-UHFFFAOYSA-N 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000011541 reaction mixture Substances 0.000 claims description 3
- MQGWDJWJIUAJFS-UHFFFAOYSA-N 2-(2,5-dioxopyrrolidin-1-yl)pentanoic acid Chemical compound CCCC(C(O)=O)N1C(=O)CCC1=O MQGWDJWJIUAJFS-UHFFFAOYSA-N 0.000 claims 2
- 150000002170 ethers Chemical class 0.000 claims 1
- 150000003949 imides Chemical group 0.000 claims 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims 1
- 102000003746 Insulin Receptor Human genes 0.000 abstract description 20
- 108010001127 Insulin Receptor Proteins 0.000 abstract description 20
- 230000000694 effects Effects 0.000 abstract description 15
- 230000001976 improved effect Effects 0.000 abstract description 5
- 238000013265 extended release Methods 0.000 abstract 1
- 235000001014 amino acid Nutrition 0.000 description 16
- 239000008280 blood Substances 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 14
- 239000003814 drug Substances 0.000 description 13
- 125000003275 alpha amino acid group Chemical group 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 11
- 102000004196 processed proteins & peptides Human genes 0.000 description 10
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 8
- 239000004472 Lysine Substances 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 7
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 6
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 6
- 125000003412 L-alanyl group Chemical group [H]N([H])[C@@](C([H])([H])[H])(C(=O)[*])[H] 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 108700002854 polyethylene glycol(B1)- insulin Proteins 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 210000004899 c-terminal region Anatomy 0.000 description 5
- 230000002641 glycemic effect Effects 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 4
- 210000000496 pancreas Anatomy 0.000 description 4
- 230000006320 pegylation Effects 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 125000000570 L-alpha-aspartyl group Chemical group [H]OC(=O)C([H])([H])[C@]([H])(N([H])[H])C(*)=O 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 3
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 238000013507 mapping Methods 0.000 description 3
- 238000007069 methylation reaction Methods 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 229920000747 poly(lactic acid) Polymers 0.000 description 3
- 239000004626 polylactic acid Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 125000003440 L-leucyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C(C([H])([H])[H])([H])C([H])([H])[H] 0.000 description 2
- 125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 description 2
- 125000000769 L-threonyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](O[H])(C([H])([H])[H])[H] 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000009615 deamination Effects 0.000 description 2
- 238000006481 deamination reaction Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000004026 insulin derivative Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 235000019419 proteases Nutrition 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 2
- 238000001542 size-exclusion chromatography Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108010089308 Insulin Detemir Proteins 0.000 description 1
- 108010057186 Insulin Glargine Proteins 0.000 description 1
- COCFEDIXXNGUNL-RFKWWTKHSA-N Insulin glargine Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)NCC(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 COCFEDIXXNGUNL-RFKWWTKHSA-N 0.000 description 1
- 125000001176 L-lysyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C([H])([H])C(N([H])[H])([H])[H] 0.000 description 1
- 125000003580 L-valyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(C([H])([H])[H])(C([H])([H])[H])[H] 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 108010092217 Long-Acting Insulin Proteins 0.000 description 1
- 102000016261 Long-Acting Insulin Human genes 0.000 description 1
- 229940100066 Long-acting insulin Drugs 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- 206010033372 Pain and discomfort Diseases 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108010076181 Proinsulin Proteins 0.000 description 1
- 244000061458 Solanum melongena Species 0.000 description 1
- 235000002597 Solanum melongena Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000022811 deglycosylation Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 230000006126 farnesylation Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940060975 lantus Drugs 0.000 description 1
- UGOZVNFCFYTPAZ-IOXYNQHNSA-N levemir Chemical compound CCCCCCCCCCCCCC(=O)NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2N=CNC=2)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2N=CNC=2)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=2C=CC=CC=2)C(C)C)CSSC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)CSSC[C@H](NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC2=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CSSC1)C(=O)N[C@@H](CC(N)=O)C(O)=O)CC1=CC=C(O)C=C1 UGOZVNFCFYTPAZ-IOXYNQHNSA-N 0.000 description 1
- 229940102988 levemir Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000007500 overflow downdraw method Methods 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000019635 sulfation Effects 0.000 description 1
- 238000005670 sulfation reaction Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003860 topical agent Substances 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
- C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Definitions
- the present invention relates to a conjugate in which a non-peptidyl polymer linker and an immunoglobulin constant region are covalently linked to amino acid residues other than the N terminus of the insulin beta chain, and a method of preparing the same.
- Insulin is a peptide secreted by beta cells of the human pancreas and plays a very important role in regulating blood glucose in the body. If the insulin is not secreted properly or secreted insulin does not work properly in the body blood sugar in the body is not controlled and rises, this condition is called diabetes. The above-mentioned cases are called type 2 diabetes, and the pancreas fails to secrete insulin to increase blood sugar type 1 diabetes. Type 2 diabetes is treated with oral hypoglycemic drugs, which are primarily chemicals, and some patients are treated with insulin. On the other hand, in the case of type 1 diabetes, administration of insulin is essential.
- the present inventors have developed a method for modifying a non-peptidyl polymer and an immunoglobulin constant region at an amino acid residue of the beta chain C terminal region of insulin after repeated studies.
- the present invention was completed by confirming that the binding force with the insulin receptor is increased rather than preparing the conjugate by modifying it at other positions.
- the present invention is an insulin and immunoglobulin Fc region is polyethylene glycol, polypropylene glycol, ethylene glycol-propylene glycol copolymer, polyoxyethylated polyol, polyvinyl alcohol, polysaccharide, Dextran, polyvinylethyl ether, biodegradable polymer, lipid polymer, chitin, hyaluronic acid, and a combination of the non-peptidyl polymer linker selected from the group consisting of a combination thereof, the non-peptidyl polymer is one end of the insulin beta
- an insulin conjugate characterized by being bound to amino acid residues other than the N terminus of the chain and the other terminus bound to the immunoglobulin Fc region.
- the non-peptidyl polymer may be linked to the amino acid residue of any one of 20 to 29 of the insulin beta chain.
- non-peptidyl polymer may be linked to the amino acid residue of any one of 25 to 29 of the insulin beta chain.
- the non-peptidyl polymer may be linked to the lysine residue at No. 29 of the insulin beta chain.
- the amino acid residue of the insulin beta chain to which the non-peptidyl polymer binds may have an amine group or a thiol group.
- the insulin is prepared by the method of any one or combination of methods, such as substitution, addition, removal and modification of some amino acids in native insulin, native insulin Variants, insulin derivatives, insulin agonists or fragments thereof.
- both ends of the non-peptidyl polymer may be bound to an amine group or a thiol group of an immunoglobulin Fc region and an insulin beta chain amino acid residue side chain, respectively.
- the amino acid may be a natural or unnatural amino acid.
- the immunoglobulin Fc region may be unglycosylated.
- the immunoglobulin Fc region may be comprised of one to four domains selected from the group consisting of CH1, CH2, CH3 and CH4 domains.
- the immunoglobulin Fc region may further comprise a hinge region.
- the immunoglobulin Fc region may be an Fc region derived from IgG, IgA, IgD, IgE or IgM.
- each domain of the immunoglobulin Fc region may be a hybrid of domains with different origins derived from immunoglobulins selected from the group consisting of IgG, IgA, IgD, IgE, IgM.
- the immunoglobulin Fc region may be a dimer or multimer consisting of short chain immunoglobulins consisting of domains of the same origin.
- the immunoglobulin Fc region may be an IgG4 Fc region.
- the immunoglobulin Fc region may be a human nonglycosylated IgG4 Fc region.
- the non-peptidyl polymer is combined with an amine group or thiol group of the amino acid residue side chain of the insulin beta chain.
- Peptides, hemithioacetals, imines or thiodioxopyrrolidinyl bonds can be formed.
- the non-peptidyl polymer may have a reactor at each end independently selected from the group consisting of aldehyde group, propionaldehyde group, butylaldehyde group, maleimide group and succinimide derivative.
- the succinimide derivatives are succinimidyl carboxymethyl, succinimidyl valerate, succinimidyl methylbutanoate, succinimidyl methylpropionate, succinimidyl butanoate, succinimidyl propionate, N- Hydroxysuccinimide or succinimidyl carbonate.
- the non-peptidyl polymer may be one having a butylaldehyde group and a succinimidyl valerate reactor at each end.
- the present invention provides a sustained preparation of insulin with increased sustained and stable in vivo comprising the insulin conjugate.
- the agent may be for treating diabetes.
- the present invention provides a method for preparing a non-peptidyl polymer comprising: (1) covalently linking a non-peptidyl polymer to an amino acid residue except for the N terminus of an insulin beta chain; (2) separating the insulin linker in which the non-peptidyl polymer is covalently bonded to the amino acid residue except for the N terminus of the insulin beta chain from the reaction mixture of (1); And (3) covalently linking an immunoglobulin Fc region to the other end of the non-peptidyl polymer of the isolated linker to produce an insulin conjugate in which both ends of the non-peptidyl polymer are bound to the immunoglobulin Fc region and insulin, respectively. It provides a method of producing an insulin conjugate, comprising the step of.
- the non-peptidyl polymer is combined with an amine group or thiol group of the amino acid residue side chain of the insulin beta chain.
- Peptides, hemithioacetals, imines or thiodioxopyrrolidinyl bonds can be formed.
- the non-peptidyl polymer may have an aldehyde derivative, a maleimide derivative, or a succinimide derivative at each end independently of the reactor.
- both ends of the non-peptidyl polymer may be bound via an amino acid residue except for the N terminus of the insulin beta chain and a thiol group or an amine group of the immunoglobulin Fc region.
- the non-peptidyl polymer may have an aldehyde derivative and a succinimide derivative at each end independently of the reactor.
- step (1) may be carried out in an alkaline environment of pH 9.0 ⁇ 2.
- the molar ratio of the insulin and the non-peptidyl polymer of step (1) may be 1: 1.5 to 1:10.
- the molar ratio of the insulin linker and the immunoglobulin Fc region of step (3) may be 1: 1 to 1:10.
- Insulin conjugates of the present invention can be usefully used for the development of high-efficiency long-acting insulin, since the binding force to the insulin receptor is significantly increased and the in vivo activity of insulin is significantly improved.
- 1a to 1b are profiles and SDS-PAGE gel images of mono-pegylated insulin purified using a Source 15S column.
- Figure 4 is a binding sensogram of the insulin conjugate to the insulin receptor.
- A) is the N terminal insulin conjugate
- B) is the B29 insulin conjugate
- the concentration of each substance from top to bottom is 1000, 500, 250, 125 , 62.5 nM.
- the present invention is an insulin and immunoglobulin Fc region is polyethylene glycol, polypropylene glycol, ethylene glycol-propylene glycol copolymer, polyoxyethylated polyol, polyvinyl alcohol, polysaccharide, Dextran, polyvinylethyl ether, biodegradable polymer, lipid polymer, chitin, hyaluronic acid, and a combination of the non-peptidyl polymer linker selected from the group consisting of a combination thereof, the non-peptidyl polymer is one end of the insulin beta
- an insulin conjugate characterized by being bound to amino acid residues other than the N terminus of the chain and the other terminus bound to the immunoglobulin Fc region.
- insulin is secreted from the pancreas when the blood sugar in the body is high to absorb sugar from the liver, muscle, and adipose tissue and store it as glycogen, and inhibits the use of energy as a source of energy by breaking down fat to regulate blood sugar.
- Eggplant is a type of bioactive peptide.
- the term 'insulin' includes not only natural insulin but also insulin agonists, precursors, derivatives, fragments, variants, and the like, preferably Natural insulin, fast-acting insulin, sustained insulin, and the like, without limitation.
- Natural insulin is a hormone secreted by the pancreas and generally regulates blood glucose in the body by promoting glucose uptake in cells and inhibiting breakdown of fat. Insulin is processed in the form of a proinsulin precursor that has no glycemic control function and becomes insulin having glycemic control function.
- the amino acid sequence of native insulin is as follows.
- the insulin is prepared by the method of any one or combination of methods, such as substitution, addition, removal and modification of some amino acids in native insulin, native insulin Variants, insulin derivatives, insulin agonists or fragments thereof.
- Insulin agonist refers to a substance that binds to the in vivo receptor of insulin and exhibits the same biological activity as insulin, regardless of the structure of insulin.
- Insulin derivatives exhibit at least 80% homology to amino acid sequences compared to native insulin, with some groups of amino acid residues chemically substituted (eg, alpha-methylation, alpha-hydroxylation), removal (eg, deamination) or modification (Eg, N-methylation, glycosylation, fatty acid) refers to a peptide having a function of regulating blood sugar in the body.
- An insulin fragment means a form in which one or more amino acids are added or deleted at the amino or carboxy terminus of insulin, and the added amino acid may be an amino acid (eg, a D-type amino acid) that does not exist in nature, and such insulin fragment is It has a glycemic control function in the body.
- Insulin variant refers to a peptide having a glycemic control function in the body as a peptide having one or more different amino acid sequences from insulin.
- the preparation methods used in insulin agonists, derivatives, fragments and variants, respectively, may be used independently and may be combined.
- the insulin peptide of the present invention also includes peptides having a glycemic control function in the body in which at least one amino acid sequence differs from the native insulin and deamination of the N-terminal amino acid residue.
- the insulin used in the present invention may be produced through a recombinant method, and may also be produced by a method synthesized through a solid phase synthesis method.
- Insulin conjugates of the present invention are characterized in that the non-peptidyl polymer having a reactor at both ends is used as a linker, and each end of the polymer is covalently bonded to the insulin beta chain and the immunoglobulin Fc region, respectively.
- both ends of the non-peptidyl polymer may be bound to an amine group or a thiol group of an immunoglobulin Fc region and an insulin beta chain amino acid residue side chain, respectively.
- the amino acid may be a natural or unnatural amino acid, but is not limited as long as it can form a covalent bond with the non-peptidyl polymer, including an amine group or a thiol group.
- the present invention provides a combination of polyethylene glycol (PEG) and immunoglobulin constant region (hereinafter referred to as immunoglobulin Fc or Fc) to improve the blood stability of insulin. Therefore, it is confirmed that the binding force to the insulin receptor is changed, and furthermore, it is characterized by identifying the binding sites that can increase the activity of the insulin binding ability is improved. For example, it was confirmed that the binding to PEG-Fc improves blood stability, but the binding does not reduce the activity by inhibiting the binding to the insulin receptor. In the case of insulin alpha chains, it is known that the activity is markedly reduced when forming a conjugate, so the optimal binding position on the beta chain of insulin was searched. As a result, it was confirmed that the binding position of the non-peptidyl polymer may be any amino acid residue having an amine group or a thiol group except for the N terminal of the insulin beta chain.
- the non-peptidyl polymer may be linked to the amino acid residue of any one of 20 to 29 of the insulin beta chain. More preferably, the non-peptidyl polymer may be linked to the amino acid residue of any one of 25 to 29 of the insulin beta chain. Even more preferably, the non-peptidyl polymer may be linked to the lysine residue at No. 29 of the insulin beta chain.
- the amino acid residue of the insulin beta chain to which the non-peptidyl polymer binds may have an amine group or a thiol group.
- it may be, but is not limited to, lysine, cysteine or derivatives thereof.
- a PEG-Fc conjugated conjugate was prepared at the N-terminus and lysine positions 29 of the insulin beta chain, and the binding force to the insulin receptor of each insulin conjugate was confirmed. It was confirmed that the PEG-Fc-coupled insulin conjugate at the lysine position 29 showed a higher binding force (about 3.6-fold) than the insulin conjugate at which the N-terminal PEG-Fc conjugated (Example 4, Table 1). As such, an increase in the binding force to the insulin receptor means an increase in the activity of the insulin conjugate.
- the binding position of the non-peptidyl polymer for maintaining the activity of the insulin and improving the stability is not limited to No. 29 of the insulin beta chain.
- native insulin can covalently bind non-peptidyl polymers through the ⁇ -amine group of the only lysine located at No. 29 of the beta chain.
- the non-peptidyl polymer may bind to the corresponding amino acid positions, and these conjugates are also included in the scope of the present invention.
- Amino acid residues of the insulin beta chain may be substituted with lysine or cysteine residues for ease of preparation in preparing a conjugate that maintains the activity of the insulin.
- an insulin conjugate can be more easily prepared using an insulin derivative in which the amino acid residue of the insulin beta chain C terminal region is substituted with a lysine or cysteine residue, and the insulin conjugate prepared using the insulin derivative is also within the scope of the present invention.
- non-peptidyl polymer refers to a biocompatible polymer having two or more repeating units linked thereto, and the repeating units are linked to each other through any covalent bonds, not peptide bonds.
- Non-peptidyl polymers usable in the present invention include polyethylene glycol, polypropylene glycol, copolymers of ethylene glycol and propylene glycol, polyoxy ethylated polyols, polyvinyl alcohol, polysaccharides, dextran, polyvinyl ethyl ether, PLA ( Biodegradable polymers such as polylactic acid, polylactic acid) and PLGA (polylactic-glycolic acid), lipid polymers, chitins, hyaluronic acid, and combinations thereof, preferably Polyethylene glycol (PEG). Derivatives thereof known in the art and derivatives which can be easily prepared at the technical level in the art are also included in the scope of the present invention.
- the disadvantage of the peptidic linker used in the fusion protein prepared by the conventional inframe fusion method is that it is easily cleaved by protease in vivo, and thus the blood half-life increase effect of the active drug by the carrier cannot be achieved as expected. will be.
- the non-peptidyl polymer that can be used in the present invention can be used without limitation as long as it can play such a role, that is, a polymer that is resistant to proteolytic enzymes in vivo.
- Non-peptidyl polymers preferably have a molecular weight in the range of 1 to 100 kDa, preferably 1 to 20 kDa.
- the non-peptidyl polymer of the present invention to be combined with the bioactive polypeptide may be used not only one kind of polymer but also a combination of different kinds of polymers.
- Non-peptidyl polymers used in the present invention have a reactor that can be combined with immunoglobulin Fc regions and protein drugs.
- the non-peptidyl polymer comprises an amine group or thiol group of the amino acid residue side chain of the insulin beta chain.
- Peptides, hemithioacetals, imines or thiodioxopyrrolidinyl bonds can be formed.
- Non-limiting examples of both terminal reactors of the non-peptidyl polymer include propionaldehyde groups, aldehyde groups such as butylaldehyde groups, maleimide groups, and succinimide derivatives.
- succinimide derivatives include succinimidyl carboxymethyl, succinimidyl valerate, succinimidyl methylbutanoate, succinimidyl methylpropionate, succinimidyl butanoate, succinimidyl propionate, and N-hydride.
- Roxysuccinimide or succinimidyl carbonate may be used, but is not limited thereto.
- a reactor capable of selectively covalently bonding an immunoglobulin Fc region with an amine group or a thiol group of an insulin beta chain amino acid residue is provided. Can be used without limitation.
- Both terminal reactors of the non-peptidyl polymer may be the same or different from each other.
- one end may have a succinimide group
- the other end may have an aldehyde group such as propionaldehyde group or butylaldehyde group.
- polyethylene glycol having a hydroxy reactor at both ends is used as a non-peptidyl polymer, it is possible to activate the hydroxy group to the various reactors by a known chemical reaction, or to use polyethylene glycol having a commercially available modified reactor.
- the protein conjugates of the invention can be prepared.
- the non-peptidyl polymer may have a butylaldehyde group and a succinimidyl valerate reactor at each end.
- the immunoglobulin Fc region refers to the heavy chain constant region 2 (CH2) and the heavy chain constant region 3, except for the heavy and light chain variable regions, heavy chain constant region 1 (CH1) and light chain constant region (CL1) of the immunoglobulin (CH3) portion, and may include a hinge portion in the heavy chain constant region.
- the immunoglobulin Fc region of the present invention has a substantially equivalent or improved effect as the natural type, except for the heavy and light chain variable regions of the immunoglobulin, some or all heavy chain constant region 1 (CH1) and / or light chain constant region It may be an extended Fc region including 1 (CL1).
- the immunoglobulin Fc region of the present invention comprises (1) CH1 domain, CH2 domain, CH3 domain and CH4 domain, (2) CH1 domain and CH2 domain, (3) CH1 domain and CH3 domain, (4) CH2 domain and CH3 Domain, (5) a combination of one or two or more domains with an immunoglobulin hinge region (or a portion of the hinge region), (6) heavy chain constant region and a dimer of each domain and light chain constant region.
- the immunoglobulin Fc region is a biodegradable polypeptide that is metabolized in vivo, it is safe to use as a carrier for drugs.
- the immunoglobulin Fc region is advantageous in terms of preparation, purification and yield of the conjugate because of its relatively low molecular weight compared to the whole immunoglobulin molecule, as well as eliminating Fab moieties that exhibit high heterogeneity because the amino acid sequence varies from antibody to antibody. This can be expected to increase significantly and to reduce the likelihood of inducing blood antigenicity.
- the immunoglobulin Fc region may be human or animal origin such as cow, goat, pig, mouse, rabbit, hamster, rat, guinea pig, etc., preferably human origin.
- the immunoglobulin Fc region may be an Fc region by IgG, IgA, IgD, IgE, IgM derived or combinations thereof or hybrids thereof. It is preferably derived from IgG or IgM, which is most abundant in human blood and most preferably from IgG known to enhance the half-life of ligand binding proteins.
- dimer or multimer when forming a dimer or multimer, means that the polypeptide encoding the single-chain immunoglobulin Fc region of the same origin forms a bond with single-chain polypeptides of different origin. do. That is, it is possible to prepare dimers or multimers from two or more fragments selected from the group consisting of Fc fragments of IgG Fc, IgA Fc, IgM Fc, IgD Fc and IgE.
- hybrid is a term used to mean that there is a sequence corresponding to two or more immunoglobulin Fc fragments of different origins within an immunoglobulin Fc region of a single chain.
- various types of hybrids are possible. That is, hybridization of a domain consisting of 1 to 4 domains from the group consisting of CH1, CH2, CH3 and CH4 of IgG Fc, IgM Fc, IgA Fc, IgE Fc and IgD Fc is possible, and may include a hinge.
- IgG can also be divided into subclasses of IgG1, IgG2, IgG3 and IgG4 and combinations or hybridization thereof are also possible in the present invention.
- the most preferred immunoglobulin Fc region for a carrier of the drug of the present invention is a non-glycosylated Fc region derived from human IgG4.
- Human-derived Fc regions are preferred over non-human-derived Fc regions that can cause undesirable immune responses, such as acting as antigens in human living organisms to produce new antibodies against them.
- the immunoglobulin Fc region may be a natural sugar chain, an increased sugar chain compared to the natural form, a reduced sugar chain or a sugar chain removed from the natural form.
- Conventional methods such as chemical methods, enzymatic methods, and genetic engineering methods using microorganisms can be used to increase or decrease such immunoglobulin Fc sugar chains.
- the immunoglobulin Fc region in which the sugar chain is removed from the Fc has a significant decrease in the binding capacity of the complement (c1q), and the antibody-dependent cytotoxicity or the complement-dependent cytotoxicity is reduced or eliminated, thereby not causing an unnecessary immune response in vivo. Do not.
- a form more consistent with the original purpose as a carrier of the drug would be the immunoglobulin Fc region from which the sugar chains have been removed or unglycosylated.
- “Deglycosylation” refers to the removal of sugar from the Fc region by using an enzyme
- “Aglycosylation” refers to the Fc region that is not glycosylated in prokaryotes, preferably E. coli. Means to produce.
- immunoglobulin Fc regions of the present invention include naturally occurring amino acid sequences as well as their sequence derivatives.
- Amino acid sequence derivatives mean that one or more amino acid residues in a natural amino acid sequence have different sequences by deletion, insertion, non-conservative or conservative substitution, or a combination thereof.
- IgG Fc amino acid residues 214 to 238, 297 to 299, 318 to 322 or 327 to 331 which are known to be important for binding can be used as suitable sites for modification.
- various kinds of derivatives are possible, such as a site capable of forming disulfide bonds, a few amino acids at the N-terminus in the native Fc, or a methionine residue may be added at the N-terminus of the native Fc. Do.
- complement binding sites such as C1q binding sites may be removed or ADCC sites may be removed to eliminate effector function.
- it may be modified by phosphorylation, sulfation, acrylation, glycosylation, methylation, farnesylation, acetylation, amylation, etc. may be modified.
- immunoglobulin Fc derivatives described above may be derivatives that exhibit the same biological activity as the immunoglobulin Fc region of the present invention but increase structural stability against heat, pH, etc. of the immunoglobulin Fc region.
- immunoglobulin constant regions may be obtained from natural forms isolated from humans and animals, such as cattle, goats, pigs, mice, rabbits, hamsters, rats, and guinea pigs, or may be transformed animal cells or microorganisms. It may be a recombinant or derivative thereof obtained from.
- the method obtained from the natural form can be obtained by separating the whole immunoglobulin from the human or animal living body, and then treating the protease. Papain is cleaved into Fab and Fc, and pepsin is cleaved into pF'c and F (ab) 2. This may be separated by Fc or pF'c using size-exclusion chromatography.
- the immunoglobulin Fc region derived from a human may be a recombinant immunoglobulin constant region obtained from a microorganism.
- the binding of the immunoglobulin Fc region to the non-peptidyl polymer is similar to that of the insulin beta chain and the non-peptidyl polymer. It is formed by covalent bonds between amine groups or thiol groups.
- the non-peptidyl polymer binds to the N terminus of the immunoglobulin Fc region or the amine group of the lysine residue in the immunoglobulin Fc region or the thiol group of the cysteine residue.
- the position of the amino acid residue to which the non-peptidyl polymer is bound on the immunoglobulin Fc region is not limited.
- the present invention provides a sustained preparation of insulin with increased activity in vivo comprising the insulin conjugate.
- the insulin sustaining agent may be for treating diabetes.
- the present invention also provides a method of treating diabetes by administering the insulin-sustaining agent to a subject in need thereof.
- administration means introducing a predetermined substance into a patient by any suitable method, and the route of administration of the conjugate may be administered through any general route as long as the drug can reach the target tissue.
- Intraperitoneal administration intravenous administration, intramuscular administration, subcutaneous administration, intradermal administration, oral administration, topical administration, intranasal administration, pulmonary administration, rectal administration and the like, but is not limited thereto.
- oral administration since the peptide is digested, it is desirable to formulate the oral composition to coat the active agent or to protect it from degradation in the stomach. It may preferably be administered in the form of an injection.
- long-acting formulations may be administered by any device in which the active agent may migrate to target cells.
- Sustained formulations comprising a conjugate of the invention may include a pharmaceutically acceptable carrier.
- Pharmaceutically acceptable carriers can be used as oral administration binders, lubricants, disintegrants, excipients, solubilizers, dispersants, stabilizers, suspending agents, pigments, flavors, etc., in the case of injections, buffers, preservatives, analgesic
- a topical agent, a solubilizer, an isotonicity agent, a stabilizer, etc. can be mixed and used, and in case of topical administration, a base, an excipient, a lubricating agent, a preservative, etc. can be used.
- formulations of the long-acting formulations of the present invention can be prepared in a variety of mixtures with the pharmaceutically acceptable carriers described above.
- oral administration it may be prepared in the form of tablets, troches, capsules, elixirs, suspensions, syrups, wafers, etc., and in the case of injections, they may be prepared in unit dosage ampoules or multiple dosage forms. And other solutions, suspensions, tablets, pills, capsules, sustained release preparations and the like.
- suitable carriers, excipients and diluents suitable for formulation include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl Cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate or mineral oil and the like can be used.
- fillers, anti-coagulants, lubricants, wetting agents, fragrances, preservatives and the like may be further included.
- the long-acting formulations of the present invention are determined by the type of drug that is the active ingredient, along with several related factors such as the disease to be treated, the route of administration, the age, sex and weight of the patient and the severity of the disease. Since the pharmaceutical composition of the present invention has excellent persistence and titer in vivo, the frequency and frequency of administration of the pharmaceutical preparations of the present invention can be significantly reduced.
- the long-acting formulations of the present invention are effective in the treatment of diabetes by insulin because they enhance the in vivo stability of the insulin and maintain its activity.
- the present invention provides a method for preparing a non-peptidyl polymer comprising: (1) covalently linking a non-peptidyl polymer to an amino acid residue except for the N terminus of an insulin beta chain; (2) separating the insulin linker in which the non-peptidyl polymer is covalently bonded to the amino acid residue except for the N terminus of the insulin beta chain from the reaction mixture of (1); And (3) covalently linking an immunoglobulin Fc region to the other end of the non-peptidyl polymer of the isolated linker to produce an insulin conjugate in which both ends of the non-peptidyl polymer are bound to the immunoglobulin Fc region and insulin, respectively. It provides a method of producing an insulin conjugate, comprising the step of.
- the non-peptidyl polymer is an amine group or thiol group of the amino acid residue side chain of the insulin beta chain and a peptide, hemithioacetal, imine or thiodioxopyrrolidinyl (thiodioxopyrrolidinyl) bonds can be formed.
- the non-peptidyl polymer may be one having an aldehyde derivative, a maleimide derivative, or a succinimide derivative at each end independently, but is not limited thereto.
- both ends of the non-peptidyl polymer will bind via an amine group or thiol group of the amino acid residue side chain of the immunoglobulin Fc region and the amino acid residue except the N terminus of the insulin beta chain, respectively.
- the non-peptidyl polymer may have an aldehyde derivative and a succinimide derivative at each end independently of the reactor.
- step (1) may be performed in an alkaline environment of pH 9.0 ⁇ 2.
- the reaction is performed in an acidic environment with a pH of less than 7, the non-peptidyl polymer may bind to the N-terminal amine group.
- the pH range can be adjusted according to the type of reactor of the non-peptidyl polymer and the type of reactor of the amino acid residues of the insulin beta chain reacting with it, such as an amine group or a thiol group.
- a PEG having a succinimide derivative as a reactor as a non-peptidyl polymer is bound to an amine group of lysine in insulin, it is adjusted to pH 9.0 to form an insulin linker selectively bound to an amine group of lysine rather than an N-terminal amine group.
- a PEG having a succinimide derivative as a reactor as a non-peptidyl polymer is bound to an amine group of lysine in insulin, it is adjusted to pH 9.0 to form an insulin linker selectively bound to an amine group of lysine rather than an N-terminal amine group.
- the reaction molar ratio of insulin to the polymer may be 1: 2, more preferably 1: 2.
- the molar ratio of the insulin linker and the immunoglobulin Fc region is 1: 1 to 1. More preferably, it may be 1: 1.2.
- a PEG linker comprising a succinimide and an aldehyde reactor independently at each end was selectively PEGylated in high yield in insulin, and the PEGylated position was expressed using a mapping method. It was confirmed that it is residue 29 of the beta chain (Figs. 2-3).
- an insulin-non-peptidyl polymer-immunoglobulin constant region conjugate was prepared.
- the binding force is about 3.6 times higher than that of the PEG-Fc conjugated conjugate at the N-terminus of insulin, which is more effective in the conjugate of the present invention. To show.
- insulin beta chains with 3.4K butyraldehyde-PEG-succinimidyl valerate (PEG, Laysan Bio, Inc., USA, each having butyl aldehyde and succinimidyl valerate as functional groups)
- PEG 3.4K butyraldehyde-PEG-succinimidyl valerate
- the molar ratio of insulin: PEG at 1: 2 and the insulin concentration at 1.5 mg / ml were reacted at room temperature for about 1 hour.
- the reaction was performed at 60.8 mM sodium borate pH 9.0, 45% isopropanol, and a source S column (GE Healthcare) using a buffer containing sodium citrate (pH 3.0), 45% ethanol and a gradient of KCl concentration was used.
- Mono PEGylated insulin was purified from the reaction solution (FIGS. 1A-1B).
- Glu-C mapping method was used to identify the binding site of 3.4K PEG in PEGylated insulin according to Example 1.
- the reaction solution was 50 mM HEPES, pH 7.5 and reacted at 25 ° C. for 8 hours. Then 50 ⁇ l of 1 N HCl was added to terminate the reaction. Mapping was performed using HPLC reversed phase chromatography and the results are shown in FIG. 2.
- the peak including amino acid number 29 of the insulin beta chain was shifted, and it was confirmed that 3.4K PEG was bound to the amino acid residue of insulin beta chain 29.
- the molar ratio of mono-PEGylated insulin and immunoglobulin Fc fragment obtained using the method of Example 1 was 1: 1.2 and the total protein concentration was reacted at 25 ° C. for 13 hours at 20 mg / ml.
- the reaction solution was 100 mM HEPES, 2M sodium chloride (NaCl), pH 8.2, 20 mM sodium cyanoborohydride was added as a reducing agent.
- Source ISO GE Healthcare
- Source ISO GE Healthcare
- the prepared conjugates were analyzed for purity on HPLC using reverse phase chromatography, ion exchange chromatography, size exclusion chromatography (FIG. 3).
- both the N-terminal and B29 insulin conjugate was confirmed to bind to the insulin receptor in proportion to the concentration.
- the binding force of these insulin conjugates to the insulin receptor is shown in Table 1.
- the B29 insulin conjugate shows a high binding rate constant value of about 1.8 times that of the N-terminal insulin conjugate. This means that the B29 insulin conjugate can bind faster with the insulin receptor compared to the N terminal insulin conjugate.
- the dissociation rate constant it can be seen that the B29 insulin conjugate is about 1.8 times slower than the N terminal insulin conjugate. This means that the B29 insulin conjugate binds more stably after binding to the insulin receptor.
- the binding force of the N-terminal and B29 insulin conjugate it was confirmed that the B29 insulin conjugate is about 3.6 times higher than the N-terminal insulin conjugate.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
인슐린 결합체 | ka (1/ms, X105) | kd (1/s, X103) | KD(nM) |
N 말단 | 0.06 ± 0.01 | 3.86 ± 0.15 | 692.5 ± 50.2 |
B29 | 0.11 ± 0.02 | 2.15 ± 0.22 | 191.5 ± 50.2 |
Claims (30)
- 인슐린 및 면역글로불린 Fc 영역이 폴리에틸렌글리콜, 폴리프로필렌글리콜, 에틸렌 글리콜-프로필렌 글리콜 공중합체, 폴리옥시에틸화폴리올, 폴리비닐알콜, 폴리사카라이드, 덱스트란, 폴리비닐에틸에테르, 생분해성 고분자, 지질 중합체, 키틴류, 히아루론산 및 이들의 조합으로 이루어진 군으로부터 선택되는 비펩타이드성 중합체 링커를 통해 연결되고, 상기 비펩타이드성 중합체는 일 말단이 인슐린 베타 체인의 N 말단을 제외한 아미노산 잔기에 결합되고 다른 말단이 면역글로불린 Fc 영역에 결합된 것을 특징으로 하는 인슐린 결합체.
- 제1항에 있어서,상기 비펩타이드성 중합체는 인슐린 베타 체인의 20 내지 29번 중 어느 하나의 아미노산 잔기에 결합된 것을 특징으로 하는 인슐린 결합체.
- 제1항에 있어서,상기 비펩타이드성 중합체는 인슐린 베타 체인의 25 내지 29번 중 어느 하나의 아미노산 잔기에 결합된 것을 특징으로 하는 인슐린 결합체.
- 제1항에 있어서,상기 비펩타이드성 중합체는 인슐린 베타 체인의 29번 라이신 잔기에 결합된 것을 특징으로 하는 인슐린 결합체.
- 제1항에 있어서,비펩타이드성 중합체가 결합하는 인슐린 베타 체인의 아미노산 잔기는 아민 그룹 또는 티올 그룹을 갖는 것인 인슐린 결합체.
- 제1항에 있어서,상기 인슐린은 천연형 인슐린, 천연형 인슐린에서 일부 아미노산이 치환(substitution), 추가(addition), 제거(deletion) 및 수식(modification) 중에 어느 하나의 방법 또는 이들 방법의 조합을 통해 제조된 변이체, 인슐린 유도체, 인슐린 아고니스트 또는 이들의 단편인 인슐린 결합체.
- 제1항에 있어서,비펩타이드성 중합체의 양 말단이 각각 면역글로불린 Fc 영역과 인슐린 베타 체인 아미노산 잔기 측쇄의 아민 그룹 또는 티올 그룹(thiol group)에 결합된 인슐린 결합체.
- 제7항에 있어서,상기 아미노산은 천연 또는 비천연 아미노산인 인슐린 결합체.
- 제1항에 있어서,면역글로불린 Fc 영역이 비당쇄화됨을 특징으로 하는 인슐린 결합체.
- 제1항에 있어서,면역글로불린 Fc 영역이 CH1, CH2, CH3 및 CH4 도메인으로 이루어진 군으로부터 선택되는 1개 내지 4개 도메인으로 이루어진 인슐린 결합체.
- 제10항에 있어서,면역글로불린 Fc 영역이 힌지영역을 추가로 포함하는 인슐린 결합체.
- 제1항에 있어서,면역글로불린 Fc 영역이 IgG, IgA, IgD, IgE 또는 IgM에서 유래된 Fc 영역인 인슐린 결합체.
- 제12항에 있어서,면역글로불린 Fc 영역의 각각의 도메인이 IgG, IgA, IgD, IgE, IgM로 이루어진 군에서 선택되는 면역글로불린에서 유래된 상이한 기원을 가진 도메인의 하이브리드인 인슐린 결합체.
- 제12항에 있어서,면역글로불린 Fc 영역이 동일한 기원의 도메인으로 이루어진 단쇄 면역글로불린으로 구성된 이량체 또는 다량체인 인슐린 결합체.
- 제12항에 있어서,면역글로불린 Fc 영역이 IgG4 Fc 영역인 인슐린 결합체.
- 제12항에 있어서,면역글로불린 Fc 영역이 인간 비당쇄화 IgG4 Fc 영역인 인슐린 결합체.
- 제1항에 있어서,비펩타이드성 중합체는 인슐린 베타 체인의 아미노산 잔기 측쇄의 아민 그룹 또는 티올 그룹과 펩티드(peptide), 헤미티오아세탈(hemithioacetal), 이민(imine) 또는 티오디옥소피롤리디닐(thiodioxopyrrolidinyl) 결합을 형성하는 것인 인슐린 결합체.
- 제1항에 있어서,비펩타이드성 중합체가 양 말단에 각각 독립적으로 알데히드 그룹, 프로피온알데히드 그룹, 부틸알데히드 그룹, 말레이미드 그룹 및 석신이미드 유도체로 이루어진 군으로부터 선택되는 반응기를 갖는 인슐린 결합체.
- 제18항에 있어서,석신이미드 유도체가 석신이미딜 카르복시메틸, 석신이미딜 발레르에이트, 석신이미딜 메틸부타노에이트, 석신이미딜 메틸프로피온에이트, 석신이미딜 부타노에이트, 석신이미딜 프로피온에이트, N-하이드록시석신이미드인 또는 석신이미딜 카보네이트인 인슐린 결합체.
- 제18항에 있어서,비펩타이드성 중합체가 양 말단에 각각 부틸알데히드 그룹과 석신이미딜 발레르에이트 반응기를 갖는 인슐린 결합체.
- 제1항 내지 제20항 중 어느 한 항의 인슐린 결합체를 포함하는 생체 내 지속성 및 안정성이 증가된 인슐린의 지속성 제제.
- 제21항에 있어서,당뇨병 치료용인 지속성 제제.
- (1) 비펩타이드성 중합체를 인슐린 베타 체인의 N 말단을 제외한 아미노산 잔기에 공유결합으로 연결하는 단계;(2) 상기 (1)의 반응 혼합물로부터 인슐린 베타 체인의 N 말단을 제외한 아미노산 잔기에 비펩타이드성 중합체가 공유결합된 인슐린 연결체를 분리하는 단계; 및(3) 분리된 연결체의 비펩타이드성 중합체의 다른 쪽 말단에 면역글로불린 Fc 영역을 공유결합으로 연결하여 비펩타이드성 중합체의 양쪽 말단이 각각 면역글로불린 Fc 영역 및 인슐린과 결합된 인슐린 결합체를 생성하는 단계를 포함하는, 제1항의 인슐린 결합체의 제조방법.
- 제23항에 있어서,비펩타이드성 중합체는 인슐린 베타 체인의 아미노산 잔기 측쇄의 아민 그룹 또는 티올 그룹과 펩티드(peptide), 헤미티오아세탈(hemithioacetal), 이민(imine) 또는 티오디옥소피롤리디닐(thiodioxopyrrolidinyl) 결합을 형성하는 것인 제조방법.
- 제23항에 있어서,비펩타이드성 중합체는 양 말단에 각각 독립적으로 알데히드 유도체, 말레이미드 유도체, 또는 석신이미드 유도체를 반응기로 갖는 것인 제조방법.
- 제23항에 있어서,비펩타이드성 중합체의 양 말단은 각각 인슐린 베타 체인의 N 말단을 제외한 아미노산 잔기 및 면역글로불린 Fc 영역의 아미노산 잔기 측쇄의 아민 그룹 또는 티올 그룹(thiol group)을 통해 결합된 것인 제조방법.
- 제23항에 있어서,비펩타이드성 중합체가 양 말단에 각각 부틸알데히드 그룹과 석신이미딜 발레르에이트 반응기를 갖는 것인 제조방법.
- 제23항에 있어서,(1) 단계는 pH 9.0±2의 알칼리 환경에서 수행되는 것인 제조방법.
- 제23항 내지 제28항 중 어느 한 항에 있어서,상기 (1) 단계의 인슐린과 비펩타이드성 중합체의 몰 비는 1:1.5 내지 1:10인 것인 제조방법.
- 제23항 내지 제28항 중 어느 한 항에 있어서,상기 (3) 단계의 인슐린 연결체와 면역글로불린 Fc 영역의 몰 비는 1:1 내지 1:10인 것인 제조방법.
Priority Applications (17)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201480009429.5A CN105229025B (zh) | 2013-02-26 | 2014-02-26 | 位点特异性胰岛素缀合物 |
AU2014221534A AU2014221534B2 (en) | 2013-02-26 | 2014-02-26 | Site-specific insulin conjugate |
US14/770,214 US10046061B2 (en) | 2013-02-26 | 2014-02-26 | Site-specific insulin conjugate |
EP14757574.0A EP2963055B1 (en) | 2013-02-26 | 2014-02-26 | Site-specific insulin conjugate |
BR112015018828-1A BR112015018828B1 (pt) | 2013-02-26 | 2014-02-26 | Conjugado de insulina sítio-específico |
JP2015559200A JP6465817B2 (ja) | 2013-02-26 | 2014-02-26 | インスリン位置特異的結合体 |
CA2899418A CA2899418C (en) | 2013-02-26 | 2014-02-26 | Site-specific insulin conjugate |
RU2015133462A RU2677800C2 (ru) | 2013-02-26 | 2014-02-26 | Сайт-специфичный конъюгат инсулина |
NZ710564A NZ710564A (en) | 2013-02-26 | 2014-02-26 | Site-specific insulin conjugate |
SG11201505615PA SG11201505615PA (en) | 2013-02-26 | 2014-02-26 | Site-specific insulin conjugate |
ES14757574T ES2738676T3 (es) | 2013-02-26 | 2014-02-26 | Conjugado de insulina específico de sitio |
MX2015009799A MX361083B (es) | 2013-02-26 | 2014-02-26 | Conjugado de insulina específico de sitio. |
SA515360887A SA515360887B1 (ar) | 2013-02-26 | 2015-08-12 | مترافق الأنسولين بموقع محدد |
PH12015501815A PH12015501815A1 (en) | 2013-02-26 | 2015-08-18 | Site-specific insulin conjugate |
IL240714A IL240714B (en) | 2013-02-26 | 2015-08-20 | Place-specific insulin clip |
ZA2015/07105A ZA201507105B (en) | 2013-02-26 | 2015-09-25 | Site-specific insulin conjugate |
HK16104800.4A HK1217202A1 (zh) | 2013-02-26 | 2016-04-27 | 位點特異性胰島素綴合物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2013-0020703 | 2013-02-26 | ||
KR20130020703 | 2013-02-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014133327A1 true WO2014133327A1 (ko) | 2014-09-04 |
Family
ID=51428525
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2014/001597 WO2014133327A1 (ko) | 2013-02-26 | 2014-02-26 | 인슐린 위치 특이적 결합체 |
Country Status (22)
Country | Link |
---|---|
US (1) | US10046061B2 (ko) |
EP (1) | EP2963055B1 (ko) |
JP (1) | JP6465817B2 (ko) |
KR (1) | KR102185311B1 (ko) |
CN (1) | CN105229025B (ko) |
AR (1) | AR094904A1 (ko) |
AU (1) | AU2014221534B2 (ko) |
BR (1) | BR112015018828B1 (ko) |
CA (1) | CA2899418C (ko) |
ES (1) | ES2738676T3 (ko) |
HK (1) | HK1217202A1 (ko) |
IL (1) | IL240714B (ko) |
MX (1) | MX361083B (ko) |
NZ (1) | NZ710564A (ko) |
PH (1) | PH12015501815A1 (ko) |
PT (1) | PT2963055T (ko) |
RU (1) | RU2677800C2 (ko) |
SA (1) | SA515360887B1 (ko) |
SG (1) | SG11201505615PA (ko) |
TR (1) | TR201910929T4 (ko) |
WO (1) | WO2014133327A1 (ko) |
ZA (1) | ZA201507105B (ko) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018526001A (ja) * | 2015-08-28 | 2018-09-13 | ハンミ ファーマシューティカル カンパニー リミテッド | 新規なインスリンアナログ及びその用途 |
US11168109B2 (en) | 2012-03-08 | 2021-11-09 | Hanmi Science Co., Ltd. | Process for preparation of physiologically active polypeptide complex |
US11434271B2 (en) | 2011-11-04 | 2022-09-06 | Hanmi Science Co., Ltd. | Method for preparing physiologically active polypeptide complex |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20160101702A (ko) * | 2015-02-17 | 2016-08-25 | 한미약품 주식회사 | 지속형 인슐린 또는 이의 아날로그 결합체 |
AR105616A1 (es) | 2015-05-07 | 2017-10-25 | Lilly Co Eli | Proteínas de fusión |
EP3517544A4 (en) | 2016-09-23 | 2020-06-03 | Hanmi Pharm. Co., Ltd. | INSULIN ANALOG HAVING REDUCED INSULIN RECEPTOR BINDING FORCE AND USE THEREOF |
EP3604328A4 (en) | 2017-03-23 | 2021-01-06 | Hanmi Pharm. Co., Ltd. | REDUCED INSULIN ANALOGUE COMPLEX FOR INSULIN RECEPTOR AND ITS USE |
WO2019066603A1 (ko) * | 2017-09-29 | 2019-04-04 | 한미약품 주식회사 | 효력이 향상된 지속성 단백질 결합체 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996032478A1 (en) | 1995-04-14 | 1996-10-17 | Genentech, Inc. | Altered polypeptides with increased half-life |
WO1997034631A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
US20090285780A1 (en) * | 2006-05-24 | 2009-11-19 | Chyi Lee | Peg linker compounds and biologically active conjugates thereof |
KR20110111267A (ko) * | 2010-04-02 | 2011-10-10 | 한미홀딩스 주식회사 | 면역글로불린 단편을 이용한 인슐린 약물 결합체 |
KR20110134210A (ko) * | 2010-06-08 | 2011-12-14 | 한미홀딩스 주식회사 | 면역글로불린 단편을 이용한 인슐린 유도체 약물 결합체 |
WO2011159895A2 (en) * | 2010-06-16 | 2011-12-22 | Indiana University Research And Technology Corporation | Single chain insulin agonists exhibiting high activity at the insulin receptor |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101135244B1 (ko) * | 2007-11-29 | 2012-04-24 | 한미사이언스 주식회사 | 인슐린 분비 펩타이드 결합체를 포함하는 비만 관련질환 치료용 조성물 |
CN102369209B (zh) * | 2009-03-20 | 2015-06-10 | 韩美科学株式会社 | 制备特异性位点生理活性多肽结合物的方法 |
CN103533952B (zh) | 2011-03-15 | 2017-02-15 | 诺沃—诺迪斯克有限公司 | 包含半胱氨酸置换的人胰岛素类似物和衍生物 |
CN102675452B (zh) * | 2011-03-17 | 2015-09-16 | 重庆富进生物医药有限公司 | 具持续降血糖和受体高结合的人胰岛素及类似物的偶联物 |
UA113626C2 (xx) * | 2011-06-02 | 2017-02-27 | Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії | |
RU2606262C2 (ru) * | 2011-06-02 | 2017-01-10 | Ханми Сайенс Ко., Лтд. | Мультимер непептидильный полимер-инсулин и способ его получения |
-
2014
- 2014-02-26 RU RU2015133462A patent/RU2677800C2/ru active
- 2014-02-26 CA CA2899418A patent/CA2899418C/en active Active
- 2014-02-26 JP JP2015559200A patent/JP6465817B2/ja active Active
- 2014-02-26 US US14/770,214 patent/US10046061B2/en active Active
- 2014-02-26 AU AU2014221534A patent/AU2014221534B2/en active Active
- 2014-02-26 WO PCT/KR2014/001597 patent/WO2014133327A1/ko active Application Filing
- 2014-02-26 KR KR1020140022948A patent/KR102185311B1/ko active IP Right Grant
- 2014-02-26 EP EP14757574.0A patent/EP2963055B1/en active Active
- 2014-02-26 CN CN201480009429.5A patent/CN105229025B/zh active Active
- 2014-02-26 ES ES14757574T patent/ES2738676T3/es active Active
- 2014-02-26 SG SG11201505615PA patent/SG11201505615PA/en unknown
- 2014-02-26 PT PT14757574T patent/PT2963055T/pt unknown
- 2014-02-26 BR BR112015018828-1A patent/BR112015018828B1/pt active IP Right Grant
- 2014-02-26 TR TR2019/10929T patent/TR201910929T4/tr unknown
- 2014-02-26 MX MX2015009799A patent/MX361083B/es active IP Right Grant
- 2014-02-26 NZ NZ710564A patent/NZ710564A/en unknown
- 2014-02-26 AR ARP140100614A patent/AR094904A1/es unknown
-
2015
- 2015-08-12 SA SA515360887A patent/SA515360887B1/ar unknown
- 2015-08-18 PH PH12015501815A patent/PH12015501815A1/en unknown
- 2015-08-20 IL IL240714A patent/IL240714B/en active IP Right Grant
- 2015-09-25 ZA ZA2015/07105A patent/ZA201507105B/en unknown
-
2016
- 2016-04-27 HK HK16104800.4A patent/HK1217202A1/zh unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996032478A1 (en) | 1995-04-14 | 1996-10-17 | Genentech, Inc. | Altered polypeptides with increased half-life |
WO1997034631A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
US20090285780A1 (en) * | 2006-05-24 | 2009-11-19 | Chyi Lee | Peg linker compounds and biologically active conjugates thereof |
KR20110111267A (ko) * | 2010-04-02 | 2011-10-10 | 한미홀딩스 주식회사 | 면역글로불린 단편을 이용한 인슐린 약물 결합체 |
KR20110134210A (ko) * | 2010-06-08 | 2011-12-14 | 한미홀딩스 주식회사 | 면역글로불린 단편을 이용한 인슐린 유도체 약물 결합체 |
WO2011159895A2 (en) * | 2010-06-16 | 2011-12-22 | Indiana University Research And Technology Corporation | Single chain insulin agonists exhibiting high activity at the insulin receptor |
Non-Patent Citations (5)
Title |
---|
H. NEURATH; R.L. HILL: "The Proteins", 1979, ACADEMIC PRESS |
HINDS ET AL.: "Effects of PEG conjugation on insulin properties", ADVANCED DRUG DELIVERY REVIEWS, vol. 54, no. 4, 1 January 2002 (2002-01-01), pages 505 - 530, XP003004966, DOI: 10.1016/S0169-409X(02)00025-X * |
JENS BRANGE; AAGE VOLUND, ADV. DRUG DELIV. REV., vol. 35, no. 2-3, 1999, pages 307 - 335 |
PETER KURTZHALS ET AL., DIABETES, vol. 49, no. 6, 2000, pages 999 - 1005 |
See also references of EP2963055A4 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11434271B2 (en) | 2011-11-04 | 2022-09-06 | Hanmi Science Co., Ltd. | Method for preparing physiologically active polypeptide complex |
US11168109B2 (en) | 2012-03-08 | 2021-11-09 | Hanmi Science Co., Ltd. | Process for preparation of physiologically active polypeptide complex |
JP2018526001A (ja) * | 2015-08-28 | 2018-09-13 | ハンミ ファーマシューティカル カンパニー リミテッド | 新規なインスリンアナログ及びその用途 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2015268199B2 (en) | Composition for treating diabetes mellitus comprising insulin and a GLP-1/glucagon dual agonist | |
WO2014133327A1 (ko) | 인슐린 위치 특이적 결합체 | |
WO2011122921A2 (en) | An insulin conjugate using an immunoglobulin fragment | |
WO2012011752A2 (en) | Novel long-acting glucagon conjugate and pharmaceutical composition comprising the same for the prevention and treatment of obesity | |
WO2012165915A2 (en) | Composition for treating diabetes comprising long-acting insulin conjugate and long-acting insulinotropic peptide conjugate | |
WO2014133324A1 (ko) | 신규한 인슐린 아날로그 및 이의 용도 | |
WO2013100704A1 (en) | A site-specific glp-2 conjugate using an immunoglobulin fragment | |
WO2015005748A1 (ko) | 수용체-매개 제거가 감소된, 생리활성 폴리펩타이드 단량체-면역글로불린 Fc 단편 결합체 및 이의 제조방법 | |
WO2011122923A2 (en) | Long-acting interferon beta formulation using immunoglobulin fragment | |
RU2624129C2 (ru) | Способ получения комплекса физиологически активного полипептида | |
US10744187B2 (en) | Insulin conjugate using an immunoglobulin fragment | |
WO2012002745A2 (en) | Factor viia complex using an immunoglobulin fragment | |
WO2014137161A1 (ko) | 생리활성 폴리펩타이드 결합체의 고수율 생산을 위한 개선된 제조 방법 | |
WO2017116191A2 (ko) | 지속형 인간 성장 호르몬 결합체의 신규 액상 제제 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201480009429.5 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14757574 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2015559200 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014757574 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2899418 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15175553 Country of ref document: CO Ref document number: MX/A/2015/009799 Country of ref document: MX |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112015018828 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2014221534 Country of ref document: AU Date of ref document: 20140226 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 240714 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14770214 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: IDP00201505396 Country of ref document: ID |
|
ENP | Entry into the national phase |
Ref document number: 2015133462 Country of ref document: RU Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 112015018828 Country of ref document: BR Kind code of ref document: A2 Effective date: 20150805 |